Search our news archive and pharma companies…
|
Today's News | Note: News feeds may no longer be available for the articles on this page.
Aeterna,
Sanofi end prostate drug pact 5:55 AM 12/18/2009
Reuters
Aeterna Zentaris will end a development deal with Sanofi-Aventis for cetrorelix treatment for benign prostatic hyperplasia following disappointing late-stage results.
...
See all stories on this topic
Vion
Pharmaceuticals Files Bankruptcy After FDA Rejects
Drug 5:32 AM 12/18/2009
Bloomberg
Vion Pharmaceuticals Inc filed for bankruptcy after the US FDA refused to approve the drug developer’s application for the Onrigin anti-cancer injection without added efficacy and safety studies.
...
See all stories on this topic
Aveo
plans to sell shares in an IPO 2:42 AM 12/18/2009
Boston Globe
Aveo Pharmaceuticals Inc plans to sell shares in an initial public offering to raise as much as $86.2 million. The company raised $165 million in venture capital and fees from strategic partners Biogen Idec and OSI Pharmaceuticals.
...
See all stories on this topic
Flu
pandemic may change US flu approach forever 5:34 PM 12/17/2009
Reuters
While they said years of work were
needed before vaccine production was up to the desired standard,
some experiments such as vaccinating children in schools
...
See all stories on this topic
Anadys
hepatitis C drug meets key study goals 1:08 PM 12/17/2009
BusinessWeek
Anadys Pharmaceuticals Inc said its experimental hepatitis C drug ANA598 is meeting key goals in a midstage clinical trial in a combination treatment with pegylated interferon and Ribavirin.
...
See all stories on this topic
Roche-licensed
diabetes drug meets two study goals 4:32 AM 12/17/2009
Reuters
Roche said its weekly diabetes treatment taspoglutide met goals in two late-stage trials. Roche licensed taspoglutide from Ipsen for the GLP-1 treatment market.
...
See all stories on this topic
Biotech
bonanza lurks in healthcare reform bills 2:12 AM 12/17/2009
Los Angeles Times
The Hatch-Waxman Act's five-year protection for chemical drugs created an annual $60-billion generics market in the US saving American consumers roughly $10 billion a year while ravaging innovators. Twelve year protection for biotech drugs is aimed at ensuring innovation.
...
See all stories on this topic
Synitron
inks licensing deal with Sanofi Pasteur 2:37 PM 12/16/2009
Bizjournals.com
Biotech company Synitron said it reached a development-and-licensing agreement with Sanofi Pasteur involving a vaccine against Staphylococcus aureus. It could be worth $149 million.
...
See all stories on this topic
FDA
Panel Votes Down New Use for OSI Cancer Drug 2:09 PM 12/16/2009
ABC News
An FDA advisory panel recommended against expanding approval of OSI Pharmaceuticals lung cancer drug Tarceva to patients who are already responding to chemotherapy.
...
See all stories on this topic
Auxilium
penis drug trial yields mixed results 11:05 AM 12/16/2009
Reuters
Auxilium Pharmaceuticals Inc's Xiaflex treatment for Peyronie's disease where a hard lump forms within the penis failed to meet three out of four criteria measuring sexual quality. Penile curvature was reduced.
...
See all stories on this topic
Achillion
shares rise on promising hepatitis C drug data 7:48 AM 12/16/2009
Reuters
Shares of Achillion Pharmaceuticals Inc were up big before the bell after the company reported promising results from an early-stage trial of its hepatitis C drug ACH-1625
...
See all stories on this topic
HIV/AIDS:
The incurable epidemic 4:55 AM 12/16/2009
Washington Post
A trial of microbicide PRO 20000 to prevent the transmission of HIV to women has failed. This comes on the heels of disappointment over what was believed to be a breakthrough in AIDS vaccine development.
...
See all stories on this topic
Senate
rejects plan to import low-cost drugs 6:50 PM 12/15/2009
The Associated Press
The Senate rejected a plan to allow Americans to import low-cost prescriptions from abroad. The Obama administration echoed safety concerns raised by the pharmaceutical industry which is supporting the Democrats' health care bill.
...
See all stories on this topic
Amgen,
Array BioPharma enter development agreement 2:33 PM 12/15/2009
Forbes
Amgen will receive exclusive worldwide rights to Array's small-molecule glucokinase activator program including potential drug compound ARRY-403.
...
See all stories on this topic
Transition
Shares Fall After Deaths in Alzheimer's Drug Study 1:23 PM 12/15/2009
Bloomberg
Transition Therapeutics Inc and partner Elan Corp said nine people died in a mid-stage clinical trial of ELND005 being developed to treat Alzheimer’s disease.
...
See all stories on this topic
<- Day Earlier | Today's News
|
